通过裂解重新激活来推进 Epstein-Barr 病毒相关恶性肿瘤的治疗策略。

Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation.

机构信息

Department of Laboratory Medicine, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510630, China; The Third School of Clinical Medicine, Southern Medical University, Guangzhou 510630, China; Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, 999000, Hong Kong Special Administrative Region of China.

出版信息

Biomed Pharmacother. 2023 Aug;164:114916. doi: 10.1016/j.biopha.2023.114916. Epub 2023 May 23.

DOI:10.1016/j.biopha.2023.114916

PMID:37229802

Abstract

Epstein-Barr virus (EBV) is a widespread human herpes virus associated with lymphomas and epithelial cell cancers. It establishes two separate infection phases, latent and lytic, in the host. Upon infection of a new host cell, the virus activates several pathways, to induce the expression of lytic EBV antigens and the production of infectious virus particles. Although the carcinogenic role of latent EBV infection has been established, recent research suggests that lytic reactivation also plays a significant role in carcinogenesis. In this review, we summarize the mechanism of EBV reactivation and recent findings about the role of viral lytic antigens in tumor formation. In addition, we discuss the treatment of EBV-associated tumors with lytic activators and the targets that may be therapeutically effective in the future.

摘要

爱泼斯坦-巴尔病毒（EBV）是一种广泛存在于人类中的疱疹病毒，与淋巴瘤和上皮细胞癌有关。它在宿主中建立了两种独立的感染阶段，潜伏和裂解。当新的宿主细胞被感染时，病毒会激活几种途径，诱导裂解 EBV 抗原的表达和传染性病毒颗粒的产生。尽管潜伏 EBV 感染的致癌作用已经确立，但最近的研究表明，裂解再激活也在肿瘤发生中起着重要作用。在这篇综述中，我们总结了 EBV 再激活的机制以及最近关于病毒裂解抗原在肿瘤形成中的作用的发现。此外，我们还讨论了用裂解激活剂治疗 EBV 相关肿瘤以及未来可能具有治疗效果的靶点。